New strategies in radiation therapy: Exploiting the full potential of protons

Clinical Cancer Research

Volumn 19, Issue 23, 2013, Pages 6338-6343

  Mohan, Radhe ^a   Mahajan, Anita ^a   Minsky, Bruce D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANATOMICAL VARIATION; ARTICLE; BIOLOGIC EFFECTIVENESS; CANCER RADIOTHERAPY; CLINICAL RESEARCH; HUMAN; INTENSITY MODULATED PROTON THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOTON; PRIORITY JOURNAL; PROTON RADIATION; PROTON THERAPY; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION ENERGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; UNCERTAINTY;

CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; NEOPLASMS; PROTONS; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84890281327     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0614     Document Type: Article

References (55)

1. Liauw SL, Connell PP, Weichselbaum RR. New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transl Med 2013;5:173sr2.
2. Paganetti H, Niemierko A, Ancukiewicz M, Gerweck LE, Goitein M, Loefier JS, et al. Relative biological effectiveness (RBE) values for proton beam therapy. Int J Rad Oncol Biol Phys 2002;53:407-21.
3. Gerweck LE, Kozin SV. Relative biological effectiveness of proton beams in clinical therapy. Radiother Oncol 1999;50:135-42.
4. Britten RA, Nazaryan V, Davis LK, Klein SB, Nichiporov D, Mendonca MS, et al. Variations in the RBE for cell killing along the depth-dose profile of a modulated proton therapy beam. Radiat Res 2013;179:21-8.
5. Girdhani S, Sachs R, Hlatky L. Biological effects of proton radiation: what we know and don't know. Radiat Res 2013;179:257-72.
6. Kuhlthau KA, Pulsifer MB, Yeap BY, Rivera Morales D, Delahaye J, Hill KS, et al. Prospective study of health-related quality of life for children with brain tumors treated with proton radiotherapy. J Clin Oncol 2012;30:2079-86.
7. Amsbaugh MJ, Grosshans DR, McAleer MF, Zhu R, Wages C, Crawford CN, et al. Proton therapy for spinal ependymomas: planning, acute toxicities, and preliminary outcomes. I Int J Rad Oncol Biol Phys 2012;83:1419-24.
8. Moeller BJ, Chintagumpala M, Philip JJ, Grosshans DR, McAleer MF, Woo SY, et al. Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy. Radiat Oncol 2011;6:58.
9. Cotter SE, Herrup DA, Friedmann A, Macdonald SM, Pieretti RV, Robinson G, et al. Proton radiotherapy for pediatric bladder/prostate rhabdomyosarcoma: clinical outcomes and dosimetry compared to intensity-modulated radiation therapy. Int J Rad Oncol Biol Phys 2011;81:1367-73.
10. MacDonald SM, Yock TI. Proton beam therapy following resection for childhood ependymoma. Childs Nerv Syst 2010;26:285-91.
11. Habrand JL, Schneider R, Alapetite C, Feuvret L, Petras S, Datchary J, et al. Proton therapy in pediatric skull base and cervical canal low-grade bone malignancies. Int J Rad Oncol Biol Phys 2008;71:672-5.
12. De Laney TF. Clinical proton radiation therapy research at the Francis H. Burr Proton Therapy Center. Technol Cancer Res Treat 2007;6:61-6.
13. Yock T, Schneider R, Friedmann A, Adams J, Fullerton B, Tarbell N. Proton radiotherapy for orbital rhabdomyosarcoma: clinical outcome and a dosimetric comparison with photons. Int J Rad Oncol Biol Phys 2005;63:1161-8.
14. Hug EB, Sweeney RA, Nurre PM, Holloway KC, Slater JD, Munzenrider JE. Proton radiotherapy in management of pediatric base of skull tumors. Int J Rad Oncol Biol Phys 2002;52:1017-24.
15. Li J, Dabaja B, Reed V, Allen PK, Cai H, Amin MV, et al. Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma. Int J Rad Oncol Biol Phys 2011;81:167-74.
16. NIH, NLM. Clinical Trials. gov. National Library of Medicine (NLM) National Institutes of Health (NIH); 2013.
17. Macdonald SM, Patel SA, Hickey S, Specht M, Isakoff SJ, Gadd M, et al. Proton therapy for breast cancer after mastectomy: early outcomes of a prospective clinical trial. Int J Rad Oncol Biol Phys 2013;86:484-90.
18. Wang X, Amos RA, Zhang X, Taddei PJ, Woodward WA, Hoffman KE, et al. External-beam accelerated partial breast irradiation using multiple proton beam configurations. Int J Rad Oncol Biol Phys 2011;80:1464-72.
19. Bush DA, Slater JD, Garberoglio C, Do S, Lum S, Slater JM. Partial breast irradiation delivered with proton beam: results of a phase II trial. Clin Breast Cancer 2011;11:241-5.
20. Knausl B, Lutgendorf-Caucig C, Hopfgartner J, Dieckmann K, Kurch L, Pelz T, et al. Can treatment of pediatric Hodgkin's lymphoma be improved by PET imaging and proton therapy? Strahlenther Onkol 2013;189:54-61.
21. Hoppe BS, Flampouri S, Lynch J, Slayton W, Zaiden R, Li Z, et al. Improving the therapeutic ratio in Hodgkin lymphoma through the use of proton therapy. Oncology (Williston Park) 2012;26:456-9, 62-5.
22. Stuschke M, Kaiser A, Abu-Jawad J, Pottgen C, Levegrun S, Farr J. Reirradiation of recurrent head and neck carcinomas: comparison of robust intensity modulated proton therapy treatment plans with helical tomotherapy. Radiat Oncol 2013;8:93.
23. Jensen AD, Nikoghosyan A, Ellerbrock M, Ecker S, Debus J, Munter MW. Re-irradiation with scanned charged particle beams in recurrent tumours of the head and neck: acute toxicity and feasibility. Radiother Oncol 2011;101:383-7.
24. Noel G, Feuvret L, Calugaru V, Dhermain F, Mammar H, Haie-Meder C, et al. Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. Acta Oncol 2005;44:700-8.
25. Gragoudas ES, Lane AM, Regan S, Li W, Judge HE, Munzenrider JE, et al. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. Arch Ophthalmol 2000;118:773-8.
26. Nomiya T, Tsuji H, Toyama S, Maruyama K, Nemoto K, Tsujii H, et al. Management of high-risk prostate cancer: radiation therapy and hormonal therapy. Cancer Treat Rev 2013. [Epub ahead of print]
27. Coen JJ, Zietman AL, Rossi CJ, Grocela JA, Efstathiou JA, Yan Y, et al. Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis. Int J Rad Oncol Biol Phys 2012;82:e25-31.
28. Coen JJ, Bae K, Zietman AL, Patel B, Shipley WU, Slater JD, et al. Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12. Int J Rad Oncol Biol Phys 2011;81:1005-9.
29. Fitzek MM, Thornton AF, Varvares M, Ancukiewicz M, McIntyre J, Adams J, et al. Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer 2002;94:2623-34.
30. Brown AP, Urie MM, Chisin R, Suit HD. Proton therapy for carcinoma of the nasopharynx: a study in comparative treatment planning. Int J Rad Oncol Biol Phys 1989;16:1607-14.
31. De Laney TF, Liebsch NJ, Pedlow FX, Adams J, Dean S, Yeap BY, et al. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Rad Oncol Biol Phys 2009;74:732-9.
32. Bonnet RB, Bush D, Cheek GA, Slater JD, Panossian D, Franke C, et al. Effects of proton and combined proton/photon beam radiation on pulmonary function in patients with resectable but medically inoperable non-small cell lung cancer. Chest 2001;120:1803-10.
33. Bush DA, Slater JD, Shin BB, Cheek G, Miller DW, Slater JM. Hypofractionated proton beam radiotherapy for stage I lung cancer. Chest 2004;126:1198-203.
34. Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao A, et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III non-small cell lung cancer. Cancer 2011;117:4707-13.
35. Chang JY, Komaki R, Wen HY, De Gracia B, Bluett JB, McAleer MF, et al. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. Int J Rad Oncol Biol Phys 2011;80:1350-7.
36. Sejpal S, Komaki R, Tsao A, Chang JY, Liao Z, Wei X, et al. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for non-small cell lung cancer. Cancer 2011;117:3004-13.
37. Bush DA, Hillebrand DJ, Slater JM, Slater JD. High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. Gastroenterology 2004;127:S189-93.
38. Kawashima M, Furuse J, Nishio T, Konishi M, Ishii H, Kinoshita T, et al. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 2005;23:1839-46.
39. Park L, Delaney TF, Liebsch NJ, Hornicek FJ, Goldberg S, Mankin H, et al. Sacral chordomas: impact of high-dose proton/photonbeam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int J Rad Oncol Biol Phys 2006;65:1514-21.
40. Terahara A, Niemierko A, Goitein M, Finkelstein D, Hug E, Liebsch N, et al. Analysis of the relationship between tumor dose inhomogeneity and local control in patients with skull base chordoma. Int J Rad Oncol Biol Phys 1999;45:351-8.
41. Shipley WU, Verhey LJ, Munzenrider JE, Suit HD, Urie MM, McManus PL, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Rad Oncol Biol Phys 1995;32:3-12.
42. Zietman AL, De Silvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:1233-9.
43. Santoni R, Liebsch N, Finkelstein DM, Hug E, Hanssens P, Goitein M, et al. Temporal lobe (TL) damage following surgery and high-dose photon and proton irradiation in 96 patients affected by chordomas and chondrosarcomas of the base of the skull. Int J Rad Oncol Biol Phys 1998;41:59-68.
44. Lomax AJ, Bohringer T, Bolsi A, Coray D, Emert F, Goitein G, et al. Treatment planning and verification of proton therapy using spot scanning: initial experiences. Med Phys 2004;31:3150-7.
45. Liu W, Zhang X, Li Y, Mohan R. Robust optimization of intensity modulated proton therapy. Med Phys 2012;39:1079-91.
46. Weber DC, Wang H, Cozzi L, Dipasquale G, Khan HG, Ratib O, et al. RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study. Radiat Oncol 2009;4:34.
47. Weber DC, Rutz HP, Pedroni ES, Bolsi A, Timmermann B, Verwey J, et al. Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: the Paul Scherrer Institut experience. Int J Rad Oncol Biol Phys 2005;63:401-9.
48. Timmermann B, Schuck A, Niggli F, Weiss M, Lomax AJ, Pedroni E, et al. Spot-scanning proton therapy for malignant soft tissue tumors in childhood:.rst experiences at the Paul Scherrer Institute. Int J Rad Oncol Biol Phys 2007;67:497-504.
49. Baumert BG, Norton IA, Lomax AJ, Davis JB. Dose conformation of intensity-modulated stereotactic photon beams, proton beams, and intensity-modulated proton beams for intracranial lesions. Int J Rad Oncol Biol Phys 2004;60:1314-24.
50. Liu W, Frank SJ, Li X, Li Y, Zhu RX, Mohan R. PTV-based IMPT optimization incorporating planning risk volumes vs robust optimization. Med Phys 2013;40:021709.
51. Stuschke M, Kaiser A, Abu Jawad J, Pottgen C, Levegrun S, Farr J. Multi-scenario based robust intensity-modulated proton therapy (IMPT) plans can account for set-up errors more effectively in terms of normal tissue sparing than planning target volume (PTV) based intensity-modulated photon plans in the head and neck region. Radiat Oncol 2013;8:145.
52. Liu W, Frank SJ, Li X, Li Y, Park PC, Dong L, et al. Effectiveness of robust optimization in intensity-modulated proton therapy planning for head and neck cancers. Med Phys 2013;40:051711.
53. Casiraghi M, Albertini F, Lomax AJ. Advantages and limitations of the 'worst case scenario' approach in IMPT treatment planning. Phys Med Biol 2013;58:1323-39.
54. Wilkens JJ, Oelfke U. Optimization of radiobiological effects in intensity modulated proton therapy. Med Phys 2005;32:455-65.
55. Frese MC, Wilkens JJ, Huber PE, Jensen AD, Oelfke U, Taheri-Kadkhoda Z. Application of constant vs. variable relative biological effectiveness in treatment planning of intensity-modulated proton therapy. Int J Rad Oncol Biol Phys 2011;79:80-8.